Drugs / Meprednisone
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00623766 Background | Jul 2008 → Sep 2009 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meprednisone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00623766 ↗ |
| Known as | Betapar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201148 ↗ |
| Known as | Meprednisona | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201148 ↗ |
| Known as | NSC-527579 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201148 ↗ |
| Known as | SCH 4358 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201148 ↗ |
| Action | Activate | “Glucocorticoid receptor agonist” CHEMBL1201148 ↗ |
| Modality | Other / unclassified | “Corticosteroid: Meprednisone” NCT00623766 ↗ |
| Target | NR3C1 | “Glucocorticoid receptor agonist” CHEMBL1201148 ↗ |